Cox-2、P63蛋白在非小细胞肺癌中的表达及意义

目的 探讨非小细胞肺癌(Non-small cell lung cancer,NSCLC)组织中环氧化酶-2(Cyclooxygenase2,COX-2)、P63的表达及其与临床病理因素的关系.方法 应用免疫组织化学S-P法分别检测78例NSCLC,(43例鳞癌,35例腺癌)组织中COX-2、P63蛋白的表达情况.结果 78例NSCLC组织中COX-2为61.5%(48/78)、P63阳性表达56.4%(44/78)其中腺癌阳性率为91.4%(32/35)明显高于鳞癌37.2%(16/43)(P＜0.01);COX-2在有淋巴结转移的NSCLC阳性表达率86.7%,亦明显高于无淋巴结转移阳性率27.3%(9/33)(P＜0.01);COX-2在临床分期Ⅰ、Ⅱ期中阳性表达为29.7%,明显低于Ⅲ、Ⅳ期中阳性表达90.2%(P＜0.01).P63蛋白在肺鳞癌组织中阳性表达率97%,而腺癌组织中阳性率则为14.3%(P＜0.01);P63在有淋巴结转移的NSCLC中阳性率为57.8%,而无淋巴结转移的阳性表达率为54.5%(P＞0.05);P63在临床分期Ⅰ、Ⅱ期NSCLC组织中阳性表达率为64.9%和P63Ⅲ、Ⅳ期中阳性表达率48.8%表达差异无显著性(P＞0.05). 结论提示COX-2在NSCLC组织中的过度表达与肺腺癌的进展以及淋巴结转移,临床分期等有密切关系,P63在肺鳞癌组织中的高表达,提示可将P63检测作为鉴别低分化肺癌的参考指标.

Expressions of Cox-2 and P63 Protein in Non-small Cell Lung Cancers and Their Meanings

Objective To study the relationship of the expressions of cyclooxygenase 2(COX-2) and P63 protein in non-small cell lung cancers (NSCLC) with the clinical pathological factors of NSCLC. Methods The expressions of cox-2 and P63 protein in 78 cases of NSCLC were determined by immunohistochemical SP technique. Results The positive rates of COX-2 and P63 protein expressions in 78 cases of NSCLC were 61.5% (48/78) and 56.4% (44/78) respectively. The positive rate (91.4%,32/35) of COX-2 expression in the adenocarcinomas was significantly higher than that (37.2%,16/43) in the squamous cell carcinomas(P<0.01). The positive rate (86.7%,39/45) of COX-2 expression in NSCLC with lymph node metastasis was significantly higher than that (27.3%,9/33) in NSCLC without lymph node metastasis(P<0.01).The positive rate (29.7%,11/37) of COX-2 expression in the clinical stage I-II NSCLC was significantly lower than that (90.2%,37/41)in the clinical stage III-IV NSCLC (P<0.01).The positive rate (90.7%,39/43) of P63 expression in the squamous cell carcinomas was significantly higher than that (14.3%,5/35) in the adenocarcinomas(P<0.01).The positive rate (57.8%,26/45) of P63 expression in NSCLC with lymph node metastasis was insignificantly higher than that (54.5%,18/33) in NSCLC without lymph node metastasis (P>0.05).The positive rate (64.9%,24/37) of P63 expression in the clinical stage I-II NSCLC was insignificantly higher than that (48.8%,20/41) in the clinical stage III-IV NSCLC (P>0.05). Conclusion It is suggested that the over-expression of COX-2 in NSCLC is closely related to the development, metastasis and clinical stage of NSCLC. The over-expression of P63 protein is of reference value to differentiating the adenocarcinomas from squamous cell carcinomas in the patients with NSCLC.